Kane Biotech
Kane Biotech is a Canadian-based biotechnology company focused on the research, development, and commercialization of products that prevent and remove microbial biofilms. Established in 2001, the company aims to improve human and animal welfare through innovative solutions to biofilm-related challenges and antimicrobial resistance. With a strong portfolio of 80 patents and patents pending, Kane Biotech is recognized as a leader in biofilm research and technology, and is listed on the TSX Venture Exchange under the symbol 'KNE' and on the OTCQB Venture Market under the symbol 'KNBIF'.
Kane Biotech
290-100 Innovation Drive, Winnipeg, Manitoba, Canada, R3T 6G2
What We Do
Biofilm Technologies
Kane Biotech develops technologies aimed at preventing and destroying biofilms, which are responsible for a significant number of human infections and healthcare costs.
Wound Care & Surgical Products
The company offers products like the revyve™ Antimicrobial Wound Gel, designed to disrupt biofilms in chronic wounds.
Animal Health Products
Kane Biotech provides oral care products for pets under the bluestem™ brand, utilizing their patented coactiv+™ technology.
Dermatology Products
Kane Dermatology focuses on non-prescription consumables for scalp conditions, including the DermaKB™ product line.
coactiv+™ Antimicrobial Wound Gel
This product is indicated for the management of ulcers, burns, and various types of wounds, providing a moist environment conducive to healing while effectively combating biofilms.
DermaKB™ Scalp Detoxifier
A scalp detoxifier designed to break down biofilms and alleviate symptoms associated with scalp conditions such as dandruff and seborrheic dermatitis.
News & Updates
Kane Biotech has announced an agreement to acquire FB Dermatology, expanding its product offerings in the dermatology sector.
The company aims to disrupt the global wound care hydrogel market with its first FDA cleared medical device and announces new partnerships.
An exploration of the origins of the company's name, reflecting its founder's legacy and the company's mission.
Kane Biotech has been featured in several news media articles, including BNN Bloomberg and Benzinga, highlighting its advancements in biotechnology and wound care.